StockData
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$77.36−0.94 (-1.20%)

Close on Nov 16, 2026Market cap $15.07BP/E –Yield –

BridgeBio Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BridgeBio Pharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$368.97M. For fiscal 2025 it was -$445.91M. The highest annual figure on record is -$40.49M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$445.91M–
FY2024Dec 31, 2024-$520.73M–
FY2023Dec 31, 2023-$527.72M–
FY2022Dec 31, 2022-$419.49M–
FY2021Dec 31, 2021-$497.93M–
FY2020Dec 31, 2020-$399.71M–
FY2019Dec 31, 2019-$253.59M–
FY2018Dec 31, 2018-$136.64M–
FY2017Dec 31, 2017-$40.49M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$44.17M–
Q2 FY2026Jun 30, 2026-$71.10M–
Q1 FY2026Mar 31, 2026-$197.28M–
Q4 FY2025Dec 31, 2025-$56.42M–
Q3 FY2025Sep 30, 2025-$109.57M–
Q2 FY2025Jun 30, 2025-$80.68M-208.0%
Q1 FY2025Mar 31, 2025-$199.24M–
Q4 FY2024Dec 31, 2024-$195.33M–
Q3 FY2024Sep 30, 2024-$180.57M–
Q2 FY2024Jun 30, 2024$74.70M–
Q1 FY2024Mar 31, 2024-$219.54M–
Q4 FY2023Dec 31, 2023-$124.82M–
Q3 FY2023Sep 30, 2023-$145.23M–
Q2 FY2023Jun 30, 2023-$113.35M–
Q1 FY2023Mar 31, 2023-$144.32M–
Q4 FY2022Dec 31, 2022-$93.24M–
Q3 FY2022Sep 30, 2022-$135.16M–
Q2 FY2022Jun 30, 2022-$30.45M–
Q1 FY2022Mar 31, 2022-$160.64M–
Q4 FY2021Dec 31, 2021-$133.90M–
Q3 FY2021Sep 30, 2021-$121.56M–
Q2 FY2021Jun 30, 2021-$91.71M–
Q1 FY2021Mar 31, 2021-$150.77M–
Q4 FY2020Dec 31, 2020-$96.26M–
Q3 FY2020Sep 30, 2020-$131.68M–
Q2 FY2020Jun 30, 2020-$87.85M–
Q1 FY2020Mar 31, 2020-$83.92M–
Q4 FY2019Dec 31, 2019-$76.20M–
Q3 FY2019Sep 30, 2019-$50.00M–
Q2 FY2019Jun 30, 2019-$68.25M–
Q1 FY2019Mar 31, 2019-$59.14M–
Q4 FY2018Dec 31, 2018-$46.41M–

More BridgeBio Pharma figures

See a number that looks wrong?